Você procurou por: lewkaferesi (Maltês - Inglês)

meta tingħata l- lewkaferesi:
timing of leukapheresis:

f’ċirkustanzi oħrajn, lewkaferesi addizzjonali huma rakkomandati.
in other circumstances, additional leukaphereses are recommended.

id-dożaġġ ta’ filgrastim għandu jinżamm sal-aħħar lewkaferesi.
filgrastim dosing should be maintained until the last leukapheresis.

1 jew 2 lewkaferesi f’ jiem 5 u 6 ta ’ spiss ikunu suffiċjenti.
1 or 2 leukaphereses on days 5 and 6 are often sufficient.

għal pazjenti li ma kellhomx kimoterapija estensiva, lewkaferesi waħda ta’ spiss tkun suffiċjenti.
for patients who have not had extensive chemotherapy, one leukapheresis is often sufficient.

lewkoċitożi ġiet osservata fid-donaturi, kif ukoll tromboċitopenija wara l- għoti ta’ filgrastrim u wara lewkaferesi .
leukocytosis was observed in donors andthrombocytopenia following filgrastim and leukapheresis was also observed in donors.

il-lewkaferesi m’għandhiex titwettaq f’donaturi li jkunu antikoagulati jew li jkollhom difetti magħrufa fl-emostasi.
leukapheresis should not be performed in donors who are anticoagulated or who have known defects in haemostasis.

il-lewkaferesi għandha titwettaq matul il-perjodu meta l-anc jitla’ minn 5.0 x 109/l.
leukapheresis should be performed during the period when the anc rises from 5.0 x 109/l.

iż-żmien ta’ lewkaferesi: lewkaferesi waħda jew tnejn f’jiem 5 u 6, li ta’ spiss ikun suffiċjenti.
the timing of leukapheresis: one or two leukaphereses on days 5 and 6 which is often sufficient.

tromboċitopenja temporanja (plejtlits < 100 x 109/l) wara l-għoti ta’ filgrastim u lewkaferesi kienet osservata f’35% tal-pazjenti studjati.
transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied.